Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review

被引：22

作者：

King, Jordan B. ^{[1
]}

Bress, Adam P. ^{[1
,2
]}

Reese, Austin D. ^{[1
]}

Munger, Mark A. ^{[1
,3
]}

机构：

[1] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA

[2] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA

[3] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA

来源：

PHARMACOTHERAPY | 2015年 / 35卷 / 09期

关键词：

heart failure with reduced ejection fraction; systolic heart failure; neprilysin inhibition; therapeutic review; pharmacotherapy; CONVERTING-ENZYME-INHIBITORS; NEUTRAL ENDOPEPTIDASE INHIBITOR; VENTRICULAR SYSTOLIC FUNCTION; NATRIURETIC PEPTIDES; RANDOMIZED TRIAL; MORBIDITY; MORTALITY; LCZ696; CANDESARTAN; ENALAPRIL;

D O I：

10.1002/phar.1629

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

There has been a 10-year hiatus in the approval of a new pharmacotherapy for patients with chronic heart failure with a reduced ejection fraction (HFrEF). Combining an angiotensin receptor blocker, valsartan, with sacubitril, an inhibitor of neprilysin, results in increasing levels of natriuretic peptides that counterbalance high circulating levels of neurohormones in HFrEF. This has resulted in the development of a new agent, LCZ696. A comprehensive overview of LCZ696, its pharmacology, its role in the pathophysiology of HFrEF, completed and future clinical trial information, specific critical issues, and the place of LCZ696 in HFrEF therapy are presented.

引用

页码：823 / 837

页数：15

共 80 条

[21] Pharmacokinetic Drug-Drug Interaction Assessment of LCZ696 (an Angiotensin Receptor Neprilysin Inhibitor) With Omeprazole, Metformin or Levonorgestrel-Ethinyl Estradiol in Healthy Subjects [J].

Gan, Lu ;

Jiang, Xuemin ;

Mendonza, Anisha ;

Swan, Therese ;

Reynolds, Christine ;

Nguyen, Joanne ;

Pal, Parasar ;

Neelakantham, Srikanth ;

Dahlke, Marion ;

Langenickel, Thomas ;

Rajman, Iris ;

Akahori, Mizuki ;

Zhou, Wei ;

Rebello, Sam ;

Sunkara, Gangadhar .

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (01) :27-39

[22]

Gibbs CR, 1999, BRIT J CLIN PHARMACO, V48, P861

[23] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:: the CHARM-Alternative trial [J].

Granger, CB ;

McMurray, JJV ;

Yusuf, S ;

Held, P ;

Michelson, EL ;

Olofsson, B ;

Östergren, J ;

Pfeffer, MA ;

Swedberg, K .

LANCET, 2003, 362 (9386) :772-776

[24] Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi) [J].

Gu, Jessie ;

Noe, Adele ;

Chandra, Priya ;

Al-Fayoumi, Suliman ;

Ligueros-Saylan, Monica ;

Sarangapani, Ramesh ;

Maahs, Suzanne ;

Ksander, Gary ;

Rigel, Dean F. ;

Jeng, Arco Y. ;

Lin, Tsu-Han ;

Zheng, Weiyi ;

Dole, William P. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04) :401-414

[25] Calculation of NNTs in RCTs with time-to-event outcomes: A literature review [J].

Hildebrandt, Mandy ;

Vervoelgyi, Elke ;

Bender, Ralf .

BMC MEDICAL RESEARCH METHODOLOGY, 2009, 9

[26]

Hjalmarson Å, 1999, LANCET, V353, P2001

[27] Pharmacokinetic Drug-Drug Interaction Assessment Between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Hydrochlorothiazide, Amlodipine, or Carvedilol [J].

Hsiao, Hsiu-ling ;

Langenickel, Thomas Heiko ;

Greeley, Michael ;

Roberts, John ;

Zhou, Wei ;

Pal, Parasar ;

Rebello, Sam ;

Rajman, Iris ;

Sunkara, Gangadhar .

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (06) :407-417

[28]

Hsiao HL, 2013, HYPERTENSION, V62

[29]

Hsiao HL, 2013, HYPERTENSION, V62

[30] Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension [J].

Kario, Kazuomi ;

Sun, Ningling ;

Chiang, Fu-Tien ;

Supasyndh, Ouppatham ;

Baek, Sang Hong ;

Inubushi-Molessa, Akiko ;

Zhang, Ying ;

Gotou, Hiromi ;

Lefkowitz, Martin ;

Zhang, Jack .

HYPERTENSION, 2014, 63 (04) :698-705

← 1 2 3 4 5 6 7 8 →